BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 6, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2009

View Archived Issues

Detailed results of CORD I study of Xiaflex in Dupuytren's contracture released

Read More

AP-1 and NF-kappaB inhibitors in early development at Bristol-Myers Squibb

Read More

Hovione's TwinCaps inhaler succesful in phase III influenza trial of CS-8958

Read More

Galenica acquires Om Pharma

Read More

Amarillo Biosciences provides update on phase II interferon alpha trial in influenza and colds

Read More

Cell Biosciences to acquire Alpha Innotech

Read More

AmorePacific describes TRPV1 antagonists for the treatment of pain

Read More

Osiris Therapeutics presents preliminary results for phase III Prochymal trials

Read More

S*Bio discloses PI3K and mTOR inhibitors as oncolytics

Read More

PDE4 inhibitors and mAChRs antagonists disclosed by GSK for respiratory diseases

Read More

Bristol-Myers Squibb presents SERT inhibitors and NK1 antagonists as anxiolytics

Read More

Medivation Technologies presents novel compounds for cognitive and psychotic disorders

Read More

Phase I/II study to determine safety/efficacy of KP-413 in atopic dermatitis

Read More

West Nile virus antibody MGAWN1 to be evaluated in phase II trial

Read More

Vivus reports results from two phase III Qnexa studies

Read More

M.D. Anderson Cancer Center and Arno Therapeutics to assess DB-67 in MDS in phase II trial

Read More

Brivanib alaninate is active as first- and second-line treatment in HCC patients

Read More

Prospective study shows tendency of menatetrenone to suppress postoperative HCC recurrence

Read More

ABT-869 exhibits promising clinical activity in Child-Pugh Type A HCC patients in phase II trial

Read More

ISTA presents preliminary results for T-Pred studies

Read More

FDA approves Bepreve for the treatment of ocular itching due to allergies

Read More

Salix receives FDA marketing approval for Metozolv ODT

Read More

Aeolus commences study of AEOL-10150 as a countermeasure to radiation

Read More

Aclidinium bromide improves pulmonary function in phase III trials; MAA filing planned for 2010

Read More

ChemGenex submits NDA to FDA for Omapro

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing